Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Equity Average (2019 - 2025)

BioNexus Gene Lab's Equity Average history spans 7 years, with the latest figure at $7.7 million for Q4 2025.

  • Quarterly results put Equity Average at $7.7 million for Q4 2025, down 12.87% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (down 12.87% YoY), and the annual figure for FY2025 was $8.5 million, down 5.8%.
  • Equity Average for Q4 2025 was $7.7 million at BioNexus Gene Lab, up from $7.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $9.5 million in Q1 2024 to a low of $5.9 million in Q2 2023.
  • The 5-year median for Equity Average is $7.2 million (2022), against an average of $7.6 million.
  • The sharpest move saw Equity Average soared 83.94% in 2021, then decreased 24.27% in 2025.
  • Year by year, Equity Average stood at $7.1 million in 2021, then dropped by 8.03% to $6.5 million in 2022, then surged by 44.96% to $9.5 million in 2023, then decreased by 6.66% to $8.9 million in 2024, then dropped by 12.87% to $7.7 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $7.7 million, $7.2 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.